The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.

Since the Trend Spotter signaled a buy on 1/10 the stock gained 60.69%.

Sinocare, a diabetes company based in Changsha, may bid as much as $4 billion to acquire Johnson & Johnson's diabetes medical device subsidiaries. With falling revenues, some of J&J's diabetes-focused companies are exiting from the US market.

Small cap stocks represent a segment that has consistently outperformed the larger caps over the long term. A portfolio should consider a stable and long-term allocation towards this segment.

Citi analyst Yigal Nochomovitz now models $300M peak revenue for sitravatinib in NSCLC with inactivating CBL mutations. The analyst keeps a Buy rating on Mirati.